AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03620227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of 350ml of placebo (0mg of nitrate, with the same color, taste and smell) 100 minutes before an exercise session.
Study NCT04655443 — intervention group
Intervention type: OTHER
Intervention: Standard Care
Description: Standard cardiovascular care
Study NCT00663988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: human transplantation
Description: Allograft composite tissue transplantation. procedure. medication
Study NCT00513500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coartem and amoxicillin
Description: Perform RDT and give Coartem for malaria and give amoxicillin for fast breathing
Study NCT00513500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Give Coartem without RDT and refer fast breathing
Study NCT03631732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food
Study NCT03631732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food
Study NCT03631732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NRTIs
Description: The following NRTIs will be administered as prescribed until Week 24 without regard to food:~abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV or AZT)
Study NCT03631732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Third Agent
Description: Any one of the following third agents will be administered as prescribed. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. :~* Non-nucleoside reverse transcriptase inhibitors (NNRTIs)~  * delavirdine (DLV)~ * efavirenz (EFV)~ * nevirapine (NVP)~ * rilpivirine (RPV)~ * doravirine (DOR)~* Integrase inhibitors~  * dolutegravir (DTG)~ * elvitegravir (EVG)~ * raltegravir (RAL)~* Protease inhibitors (PIs)~  * atazanavir (ATV)~ * darunavir (DRV)~ * lopinavir (LPV)~ * nelfinavir NFV)~ * saquinavir (SQV)~ * tipranavir (TPV)~* Chemokine co-recptor 5 (CCR5) antagonist --maraviroc (MVC)
Study NCT04963556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Red Bull
Description: Drinking of Red Bull before exercise
Study NCT04963556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Bull
Description: Drinking of Red Bull before exercise
Study NCT01640314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell derived subunit trivalent nonadjuvanted vaccine
Description: A single 0.5 mL dose of the cell derived subunit trivalent nonadjuvated influenza vaccine (TIVc) supplied in prefilled syringes and administered intramuscularly in the deltoid muscle (preferably) of the non dominant arm.
Study NCT00330902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine-pyrimethamine (SP) plus artesunate (AS)
Description: sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)
Study NCT00330902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine (PQ) plus SP+AS
Description: single dose of primaquine on day 4
Study NCT00385632 — intervention group
Intervention type: DRUG
Intervention: Antiretroviral Regimens
Description: Various antiretroviral therapy combinations already being administered to participants
Study NCT03051360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCSK9 Inhibitor [EPC]
Description: Patients will receive PCSK9 inhibitor by a biweekly injection
Study NCT03051360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients will receive Placebo by a biweekly injection
Study NCT03784976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga Therapy
Description: 2 weekly yoga class (1.25 hours each)
Study NCT02463175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte
Description: Boluses of 5ml/kg of plasmalyte
Study NCT02463175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDT)
Description: Intraoperative goal-directed fluid therapy (GDT)
Study NCT04356560 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 test, polymerase chain reaction for SARS-CoV-2
Description: surveillance
Study NCT02611089 — intervention group
Intervention type: PROCEDURE
Intervention: Tissue biopsy
Description: Sampling of tissue as described.
Study NCT03061981 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.
Study NCT03061981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.
Study NCT03061981 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.
Study NCT03061981 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DA-1241
Description: After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .
Study NCT03061981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA-1241
Description: After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .
Study NCT03043248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-700
Description: repeated oral administration
Study NCT03043248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: single oral administration with/without TRK-700
Study NCT03043248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: single oral administration with/without TRK-700
Study NCT02510027 — intervention group
Intervention type: OTHER
Intervention: HPV screening and triage tests
Description: All cervical and/or vaginal specimens are tested for hrHPV using the Cobas® 4800 HPV test. Triage testing will be performed on all participants with a positive HR-HPV test declared consent at recruitment visit: HPV16/18 genotyping, Cobas® 4800 HPV test, HPV16/18/45 genotyping, BD OnclarityTM HPV Assay, OncoE6 Cervical Test, Liquid based cytology with Papanicolaou stain and p16INK4a/ Ki-67 immunostain.
Study NCT02194127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthocyan capsules
Study NCT02194127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03869359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet with gluten powder
Description: The subjects will sprinkle gluten powder over their meals, twice a day. (14 g/day vital gluten: Real Foods, Edinburgh, United Kingdom). Plastic sachet marked with B (WePack, Derbyshire, United Kingdom). Free of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
Study NCT03869359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet with placebo powder
Description: The subjects will sprinkle placebo powder over their meals, twice a day. (14 g/day rice starch: Doves Farm Foods Ltd., Berkshire, United Kingdom) Plastic sachets marked with A (WePack, Derbyshire, United Kingdom). Low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
Study NCT04133532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: metoprolol 50 mg daily for three months
Study NCT01776515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride/Acetaminophen Tab.
Study NCT01776515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride/Acetaminophen SR Tab.
Study NCT00385255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix®
Description: GSK Biologicals' inactivated influenza split virus vaccine.
Study NCT00385255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
Study NCT04304716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia
Description: Block performed is an indwelling wound bed or popliteal catheter placed intraoperatively
Study NCT01825707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-YH4808 200 mg
Description: \[14C\]-YH4808 200 mg (oral) on day1
Study NCT01277549 — intervention group
Intervention type: DEVICE
Intervention: Mononuclear cell collection.
Description: Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.
Study NCT02657408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Study NCT02657408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00583362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab 10mg/kg IV over one hour every 28 days
Study NCT03672097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel, oral tablets, containing 3.75 mg per tablet
Study NCT03346642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and histocompatibility leukocyte antigen (HLA) expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
Study NCT03346642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVD chemotherapy
Description: GVD regimen is a chemotherapy regimen consisted by Gemcitabine, Vinorelbine and Doxorubicine. Patients will be administrated with Gemcitabine 0.8 g/m2, Vinorelbine 30mg and Doxorubicin 20mg/m2 intravenously infusion.
Study NCT03346642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
Study NCT01040234 — intervention group
Intervention type: PROCEDURE
Intervention: Bilateral dual TAP block
Description: Bupivacaine 2.5 mg/ml 15 ml per injection. 4 injections per patient according to dual TAP block procedure
Study NCT03288909 — intervention group
Intervention type: OTHER
Intervention: MRI
Study NCT02806583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: structured support groups
Description: Telephone-based Support Groups, information booklet and telephone-based preparatory meeting prior to the telephone-based support groups
Study NCT03961503 — intervention group
Intervention type: DRUG
Intervention: Daptomycin (DAP) treatment
Description: Group DAP : Daptomycin was administered at a dose of 8 mg/kg in thirty-minutes intravenous infusion every 24 hours in patients without severe impairment of kidney function or every 48 hours in case of GFR below 30 ml/min/m2. The creatine-kinase (CK) level was measured before the initiation of DAP and at least once a week to assess the occurrence of muscular toxicity defined by an increase of CK up to 3-fold the upper superior limit without any evidence of member ischaemia.
Study NCT03961503 — intervention group
Intervention type: DRUG
Intervention: Vancomycin (VAN) treatment
Description: Group VAN : Vancomycin intravenous treatment was initiated by a loading dose of 30 mg/kg in 1 hour and followed by a continuous maintenance infusion dosing between 15 and 30 mg/kg/d. The VAN dose was adapted to achieve a target serum vancomycin steady-state concentration of 20-30 mg/L assessed by a daily pharmacologic monitoring (therapeutic drug monitoring).
Study NCT02115204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Study NCT02115204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT02115204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT02115204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02115204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02115204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT02115204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Study NCT02995109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z11-004)
Study NCT02995109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study NCT04455880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity
Description: SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity. The stiffer the tissue, the higher shear wave velocity is measured. Elastographic examinations were performed by physicians using Samsung HS70A ultrasound system with a Samsung CA1-7A convex transducer and S-Shear wave technique. During the examination, patients were lying in supine position, breathing levels kept steady to prevent noise and artifacts and minimum pressure were applied on the transducer to eliminate misleading tissue compression. A region of interest (ROI) box of 10 × 10 mm was positioned on placenta and six measurements were obtained from central and peripheral zones of placenta while avoiding vascular structures
Study NCT02451215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Interstitial Thermotherapy (LITT)
Description: Magnetic resonance imaging (MRI)-guided laser interstitial thermal therapy (LITT) is a minimally invasive surgical option to treat CNS tumors. LITT uses laser energy delivered to a target (i.e. CNS tumor) through a fiberoptic catheter, which results in damage to intracellular proteins and DNA, and subsequent cell death. LITT provides a sharp demarcation between ablated and unharmed tissue, which, when combined with the ability to monitor and control the ablation via MR thermal imaging, results in a high level of precision and control.
Study NCT03163797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MRI for evaluation
Description: Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test. They will also undergo low dose chest CT on the same day before PET/MRI. In the posttreatment period, baseline whole body MRI will be obtained 3 months after chemoradiation. Thereafter, the patients will then be followed up also with alternative extend-field CT and whole body MRI by every 6 months. If tumor recurrence is confirmed or highly suspected, PET/MRI will also be performed for tumor re-staging.
Study NCT01438580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Patients randomised to receive warfarin were initiated on treatment at the baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range.
Study NCT01438580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 100mg aspirin was administrated every day
Study NCT01172717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease
Study NCT02487017 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcatheter Arterial Chemoembolization (TACE)
Description: Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml,the perfusion time should not be less than 20 min
Study NCT02487017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml, the perfusion time should not be less than 20 min~DC-CIK:~8×10\^9 DC-CIK cells for each infusion, IV (in the vein) for each infusion at least 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32
Study NCT01419652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hold hypoglycemic meds
Description: continue versus hold hypoglycemic medications
Study NCT02639000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embryo transfer
Description: Embryo transfer of maximum of 2 embryos at cleavage or blastocyst stage
Study NCT02639000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Embryo transfer of maximum of 2 embryos at cleavage or blastocyst stage
Study NCT04360759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine or hydroxychloroquine
Description: Chloroquine has in vitro antiviral activity against many viruses, including SARS-CoV-1 and SARS-CoV-2. Chloroquine inhibits coronavirus replication at in vitro concentrations that are not cytotoxic and within a range of blood concentrations achievable during standard antimalarial treatment. Chloroquine inhibits viral replication through interference with glycosylation of coronavirus ACE2 receptors, required for viral entry, and downstream phagolysosome alkalisation, interfering with the low-pH-dependent steps of viral fusion and uncoating. Chloroquine also has anti-inflammatory properties and could provide benefit through this mechanism in Covid-19, where a cytokine storm has been described in critically ill patients. Hydroxychloroquine is a less toxic metabolite of chloroquine, has similar anti-inflammatory properties, and is more potent against SARS-CoV-2 in vitro.
Study NCT00978315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
Study NCT03122951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ovulation test use
Description: Normal use of The Clearblue® Advanced Ovulation Test according to Information for use instructions
Study NCT02912858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko plus R-2
Description: The gekoTM plus R-2 devices (acting on the common peroneal nerve) and IPC devices will be activated for 10mins prior to measuring blood flow.~The sequence of application of IPC and gekoTM plus R-2 devices will be randomly selected with 10 minutes recovery between active therapies.
Study NCT04176484 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview.
Study NCT00978315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Miglyol oil
Description: Miglyol oil will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
Study NCT01501305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mineral solution
Description: Rehydration mineral solution
Study NCT01501305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carob powder with probiotics
Description: 7 1/2 grams of carob powder and probiotic twice daily for one week or until diarrhea is gone
Study NCT03371615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-regurgitation infant formula
Description: Anti regurgitation infant formula
Study NCT03371615 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anti-regurgitation infant formula
Description: Anti regurgitation infant formula
Study NCT03358888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal with as needed opioids
Description: Multi-modal with as needed oxycodone and tramadol provided for break-through pain
Study NCT03358888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal with one week of opioids offered
Description: Multi-modal with only one week of oxycodone and tramadol provided for emergency pain relief only
Study NCT03358888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: This arm follows standard of care post-operative pain management with oxycodone, tramadol, and acetametophin
Study NCT00436371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: Oral tablets